EnnoDC Presents Positive Phase I AMV Data at CROI 2025
EnnoDC’s Phase I ANRS VRI06 trial demonstrated that its Antibody Mediated Vaccine (AMV) technology induces a safe, durable, and...
Acquisitions AI in Clinical Trials Analysis Article Artificial Intelligence in Clinical Trials Clinical Research Clinical Trial Innovation Clinical Trial Management System Clinical Trial Patient Engagement Clinical Trial Payments Clinical Trial Quality Clinical Trial Risk Management Clinical Trials Clinical Trial Tech Conference Coverage CTMS Data Analysis Data Management DCT Decentralized Clinical Trials DHT Digital Health Technologies eClinical Tech News eCOA eConsent EDC Executive Interviews FDA FDA Guidance GCP ICH E6 Liver Clinical Trials News Oncology Opinion Pfizer Protocol RBQM RWD RWE Solid Tumors sponsor Stanford Thyroid Tufts CSDD
EnnoDC’s Phase I ANRS VRI06 trial demonstrated that its Antibody Mediated Vaccine (AMV) technology induces a safe, durable, and...
BioAdaptives, Inc. (OTC: BDPT) has completed dosage trials for its weight loss product, Zeranoviaâ„¢, showing significant weight loss (5-7...
Kane Biotech Inc. received approval from the University of Miami Health System’s Internal Review Board to begin a clinical...
Mainz Biomed has secured an exclusive license agreement with Liquid Biosciences for a portfolio of mRNA biomarkers aimed at...
Tempest Therapeutics has received FDA clearance for a Phase 2 clinical trial of TPST-1495, a dual prostaglandin E2 (PGE2)...
PDS Biotechnology Corporation has received FDA clearance for its Investigational New Drug (IND) application to evaluate a combination therapy...
Unicycive Therapeutics will present data on oxylanthanum carbonate (OLC) for treating hyperphosphatemia in chronic kidney disease (CKD) patients on...
Avextra Pharma’s cannabis-based medicine, Avextra 10/10 (a 1:1 THC/CBD extract), demonstrated superior efficacy and tolerability in treating chemotherapy-induced neuropathic...
aTyr Pharma announced a publication in Science Translational Medicine detailing the mechanism of action of efzofitimod, its lead therapeutic...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, has launched a Phase 2 clinical...